PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted pill shows promise for hard-to-treat cancers with rare mutations
Disease control Recruiting nowThis study tests a drug called avapritinib in people with advanced solid tumors that have certain genetic changes (CKIT or PDGFRA mutations). The goal is to see if the drug can shrink or control the cancer. About 50 adults with cancers like melanoma, sarcoma, or breast, lung, or …
Matched conditions: PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
New drug cocktail shows promise for tough stomach cancers
Disease control Recruiting nowThis early-phase trial is testing a combination of two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be removed by surgery. Pembrolizumab helps the immune system attack cancer cells, while lenvati…
Matched conditions: PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:28 UTC